跳转至内容
Merck
CN

Y0000299

Fluphenazine sulfoxide

European Pharmacopoeia (EP) Reference Standard

别名:

Fluphenazine sulphoxide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H26F3N3O2S
CAS号:
分子量:
453.52
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

fluphenazine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

InChI

1S/C22H26F3N3O2S/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)31(21)30)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2

InChI key

UFPPOFUTIWYLNR-UHFFFAOYSA-N

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Fluphenazine sulfoxide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 3 Oral - Repr. 1A

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

K K Midha et al.
Journal of pharmacological methods, 19(1), 63-74 (1988-03-01)
Antisera to fluphenazine sulfoxide were raised in New Zealand white rabbits to an immunogen synthesized by covalent linkage of bovine serum albumin to 10-[[3-[4-(4-carboxybutyl)-1-piperazinyl] propyl]]-2-trifluoromethyl-10H-phenothiazine 5-sulfoxide. With use of an antiserum, a radioimmunoassay for fluphenazine sulfoxide was developed that is
S R Marder et al.
The British journal of psychiatry : the journal of mental science, 158, 658-665 (1991-05-01)
The levels of fluphenazine and fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of fluphenazine decanoate every two weeks were monitored. Patients treated with 25 mg of fluphenazine decanoate required three
K K Midha et al.
Journal of psychiatry & neuroscience : JPN, 19(4), 254-264 (1994-07-01)
This review covers some recent work on: 1. The effects of route of administration on the pharmacokinetics of fluphenazine and some of its metabolites; 2. The clinical pharmacokinetics of fluphenazine in acute patients medicated with oral fluphenazine; 3. The clinical
K K Midha et al.
Psychopharmacology, 93(3), 369-373 (1987-01-01)
Highly sensitive radioimmunoassays were applied to study the sulfoxidation of fluphenazine in 30 schizophrenic patients maintained on either 5 mg or 25 mg fluphenazine decanoate by intramuscular injection every 14 days over a period of 6 months. The presence of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门